FGP
CRMD icon

Freestone Grove Partners’s CorMedix CRMD Stock Holding History

Freestone Grove Partners’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70.2K Buy
+10,332
New +$76.4K ﹤0.01% 823

Other funds holding CRMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Freestone Grove Partners's CRMD Position: Q1 2026 in Review

Freestone Grove Partners opened a new position in CorMedix (CRMD) in Q1 2026: 10,332 shares worth $70.2K. The stake represents ﹤0.01% of the portfolio and ranks #823 among its holdings.

187 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

  • Freestone Grove Partners held 10,332 shares of CorMedix worth $70.2K as of Q1 2026.
  • CorMedix was a new Freestone Grove Partners position in Q1 2026.
  • CorMedix made up ﹤0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #823 holding.
  • 187 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.